Integra Lifesciences Holdings Corp (NASDAQ:IART) Short Interest Up 7.8% in January

Integra Lifesciences Holdings Corp (NASDAQ:IART) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 1,380,000 shares, an increase of 7.8% from the January 15th total of 1,280,000 shares. Currently, 1.9% of the shares of the company are sold short. Based on an average daily trading volume, of 411,200 shares, the days-to-cover ratio is currently 3.4 days.

In other news, major shareholder Richard E. Caruso sold 491,205 shares of the firm’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $59.42, for a total value of $29,187,401.10. Following the transaction, the insider now directly owns 134,134 shares in the company, valued at approximately $7,970,242.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Eric Schwartz sold 4,007 shares of the stock in a transaction dated Thursday, December 5th. The stock was sold at an average price of $62.25, for a total transaction of $249,435.75. Company insiders own 4.50% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the business. First National Bank of Omaha increased its stake in Integra Lifesciences by 8.8% during the 4th quarter. First National Bank of Omaha now owns 45,430 shares of the life sciences company’s stock valued at $2,648,000 after buying an additional 3,675 shares during the period. Vaughan Nelson Investment Management L.P. increased its stake in Integra Lifesciences by 1.5% during the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 862,680 shares of the life sciences company’s stock valued at $51,822,000 after buying an additional 12,728 shares during the period. Mackay Shields LLC acquired a new position in Integra Lifesciences during the 3rd quarter valued at about $1,739,000. Public Employees Retirement System of Ohio increased its stake in Integra Lifesciences by 15.4% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 82,692 shares of the life sciences company’s stock valued at $4,967,000 after buying an additional 11,028 shares during the period. Finally, Man Group plc increased its stake in Integra Lifesciences by 974.7% during the 3rd quarter. Man Group plc now owns 43,247 shares of the life sciences company’s stock valued at $2,597,000 after buying an additional 39,223 shares during the period. 79.94% of the stock is currently owned by hedge funds and other institutional investors.

Integra Lifesciences stock traded down $0.12 during trading hours on Friday, hitting $58.93. 233,824 shares of the company traded hands. The firm’s 50-day simple moving average is $57.50 and its two-hundred day simple moving average is $59.62. Integra Lifesciences has a 1-year low of $46.07 and a 1-year high of $65.09.

A number of analysts recently weighed in on IART shares. Wells Fargo & Co set a $62.00 price objective on shares of Integra Lifesciences and gave the stock a “hold” rating in a report on Friday, October 25th. SunTrust Banks started coverage on shares of Integra Lifesciences in a report on Friday, January 3rd. They issued a “buy” rating and a $56.00 price objective on the stock. Oppenheimer set a $68.00 price objective on shares of Integra Lifesciences and gave the stock a “buy” rating in a report on Friday, October 25th. Piper Jaffray Companies cut shares of Integra Lifesciences from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $59.00 to $58.00 in a report on Tuesday, January 7th. Finally, BidaskClub cut shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a report on Tuesday, January 7th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. Integra Lifesciences currently has an average rating of “Hold” and an average target price of $62.17.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

See Also: What is an overbought condition?

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit